2mov: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 3: Line 3:
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[2mov]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2MOV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2MOV FirstGlance]. <br>
<table><tr><td colspan='2'>[[2mov]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2MOV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2MOV FirstGlance]. <br>
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=IOR:N~5~-[(5R)-5-METHYL-4-OXO-4,5-DIHYDRO-1H-IMIDAZOL-2-YL]-L-ORNITHINE'>IOR</scene><br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=IOR:N~5~-[(5R)-5-METHYL-4-OXO-4,5-DIHYDRO-1H-IMIDAZOL-2-YL]-L-ORNITHINE'>IOR</scene></td></tr>
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2mov FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2mov OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2mov RCSB], [http://www.ebi.ac.uk/pdbsum/2mov PDBsum]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2mov FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2mov OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2mov RCSB], [http://www.ebi.ac.uk/pdbsum/2mov PDBsum]</span></td></tr>
<table>
</table>
== Function ==
[[http://www.uniprot.org/uniprot/RAGE_HUMAN RAGE_HUMAN]] Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space.<ref>PMID:19906677</ref> 
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 18: Line 20:
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Bohme, D.]]
[[Category: Bohme, D]]
[[Category: Burz, D S.]]
[[Category: Burz, D S]]
[[Category: Hoffman, R.]]
[[Category: Hoffman, R]]
[[Category: Rai, V.]]
[[Category: Rai, V]]
[[Category: Ray, R.]]
[[Category: Ray, R]]
[[Category: Shekhtman, A.]]
[[Category: Shekhtman, A]]
[[Category: Singer, D.]]
[[Category: Singer, D]]
[[Category: Xue, J.]]
[[Category: Xue, J]]
[[Category: Protein binding]]
[[Category: Protein binding]]
[[Category: Protein/ligand]]
[[Category: Protein/ligand]]